Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide vs placebo in non-functioning pituitary macroadenoma (Ga-68 DOTATATE PET/CT positive)
2015-001234-22Phase 3Completed
- Sponsor
- Academic Medical Center
- Start
- Jul 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-functioning pituitary macroadenoma (NFPM) and pituitary adenoma comparing Lanreotide autosolution with Placebo (2 arms). Primary endpoint: Change in cranio-caudal NFMA size over 18 months. Started Jul 2015; status: completed.
02
Drugs
lanreotide
03
Conditions
non-functioning pituitary macroadenoma (NFPM)pituitary adenoma
Beyond the preview
Go deeper on 2015-001234-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001234-22.